News

Cabozantinib Plus Atezolizumab Demonstrates Promise Among Patients With Metastatic Castration-Resistant Prostate Cancer and Soft-Tissue Metastases

08/19/2025

Stephanie Holland

According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...

According to results from the...

08/19/2025

Oncology

Conference Coverage

Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer

08/12/2025

Nicholas James, MD

Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...

Nick James, MD, PhD, discusses...

08/12/2025

Oncology

News

NRG1 May Predict Incidence of CRPC Among Patients With Prostate Cancer

08/05/2025

Allison Casey

NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.

NRG1 levels prior to ADT may...

08/05/2025

Oncology

FDA Approval

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

06/03/2025

Stephanie Holland

Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.

Based on results from the...

06/03/2025

Oncology

Conference Coverage

Lower-Dose Abiraterone Non-Inferior to Standard Dose for Metastatic Castration-Resistant Prostate Cancer

06/02/2025

Emily Estrada

A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.

A phase 3 non-inferiority trial...

06/02/2025

Oncology

Conference Coverage

Lower-Dose Abiraterone Non-Inferior to Standard Dose for Metastatic Castration-Resistant Prostate Cancer

06/02/2025

Emily Estrada

A phase 3 non-inferiority trial...

06/02/2025

Oncology

News

Addition of Pembrolizumab Fails to Improve Outcomes for Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer

05/28/2025

Stephanie Holland

Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

Results from the phase 3...

05/28/2025

Oncology

News

Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy Fails to Improve Survival for Patients With Metastatic Hormone-Sensitive Prostate Cancer

05/20/2025

Stephanie Holland

According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.

According to results from the...

05/20/2025

Oncology

News

Adding Pembrolizumab to Docetaxel Does Not Improve Survival Outcomes for Metastatic Castration-Resistant Prostate Cancer

04/21/2025

Stephanie Holland

According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.

According to results from the...

04/21/2025

Oncology

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...

Based on results from the...

03/28/2025

Oncology

Recent News

News

Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL

09/26/2025

Emily Estrada

The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.

The implementation of R-ICE...

09/26/2025

Oncology

News

PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL

09/26/2025

Emily Estrada

Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.

Treatment of R/R diffuse large...

09/26/2025

Oncology

News

Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies

09/26/2025

Emily Estrada

Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Compared with traditional...

09/26/2025

Oncology

FDA Approval

FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

09/25/2025

Stephanie Holland

The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.

The FDA has approved...

09/25/2025

Oncology

News

Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors

09/25/2025

Allison Casey

Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.

Pexidartinib showed sustained...

09/25/2025

Oncology

News

Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma

09/24/2025

Emily Estrada

For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.

For patients with...

09/24/2025

Oncology

News

First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer

09/23/2025

Stephanie Holland

Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...

Results from the phase 2/3...

09/23/2025

Oncology

News

Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.

According to a phase 2a trial,...

09/23/2025

Oncology

News

Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.

According to an analysis of the...

09/23/2025

Oncology

News

Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer

09/22/2025

Stephanie Holland

According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...

According to results from the...

09/22/2025

Oncology